Table 2.
Antimicrobial susceptibility of P. aeruginosa clinical isolates obtained from patients at a hospital center in China
| Antimicrobial | %Susceptible
|
P-value | |||||
|---|---|---|---|---|---|---|---|
| 2012 (n=370) | 2013 (n=344) | 2014 (n=406) | 2015 (n=414) | 2016 (n=486) | 2017 (n=221) | ||
| Amikacin | 70.6 | 74 | 60 | 69 | 88.5 | 94.3 | <0.001 |
| Ceftazidime | 71.5 | 75 | 73 | 66 | 78.5 | 84.9 | <0.001 |
| Ciprofloxacin | 64.7 | 66 | 79 | 79 | 70 | 79.3 | <0.001 |
| Colistin | 97.6 | 100 | 100 | 100 | 100 | 100 | NS |
| Gentamicin | 63.7 | 62 | 53 | 70 | 76 | 85.7 | <0.001 |
| Meropenem | 71.5 | 76 | 73 | 75 | 80 | 83.8 | <0.001 |
| Piperacillin/tazobactam | 78.7 | 82 | 93 | 85 | 68 | 79.7 | <0.001 |
| Cefoperazone/sulbactam | 70 | 82 | 76 | 75.6 | 75 | 79.8 | <0.001 |
| Imipenem | 81.7 | 84 | 57 | 45 | 79 | 80.7 | <0.001 |
| Tigecycline | 100 | 100 | 99 | 98 | 98 | 98 | NS |
| % of isolates with the MDR or XDR phenotype | |||||||
| MDR | 20 | 22 | 18.5 | 17 | 17.4 | 15 | 0.04 |
| XDR | 5.8 | 4.9 | 3.5 | 2.1 | 1.2 | 1 | nd |
Note: nd, statistical analysis not performed for the XDR subset due to the small number of isolates.
Abbreviations: MDR, multidrug resistant; nd, no data; NS, not significant; P. aeruginosa, Pseudomonas aeruginosa; XDR, extensively drug resistant.